A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity
Sponsor: Novo Nordisk A/S
A PHASE3 clinical study on Obesity, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 13 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .